Deals

ChemPartner and BioBAY Open Arsenal Innovation Center in Massachusetts – Bridging Suzhou and Boston Life Science Ecosystems
ChemPartner PharmatechSHE: 300149

ChemPartner and BioBAY Open Arsenal Innovation Center in Massachusetts – Bridging Suzhou and Boston Life Science Ecosystems

ChemPartner Pharmatech Co., Ltd (SHE: 300149) announced that the Arsenal Innovation Center, established in collaboration with BioBAY – the Suzhou‑based life sciences innovation park – has officially opened in Watertown,…

Vir Biotechnology and Gilead Strike Collaboration to Engineer Three PRO‑XTEN Dual‑Masked T‑Cell Engagers – Deal Worth Up to USD 1.88 Billion in Milestones

Vir Biotechnology and Gilead Strike Collaboration to Engineer Three PRO‑XTEN Dual‑Masked T‑Cell Engagers – Deal Worth Up to USD 1.88 Billion in Milestones

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
HitGen and BioAge Launch Phase I Study of BGE‑102, a Novel NLRP3 Inhibitor
BioAge LabsHitGen

HitGen and BioAge Launch Phase I Study of BGE‑102, a Novel NLRP3 Inhibitor

Siemens Healthineers Diagnostics Sale: Blackstone, CVC, KKR Explore €6 B Deal
ETR: SHLFinance

Siemens Healthineers Diagnostics Sale: Blackstone, CVC, KKR Explore €6 B Deal

Baheal’s 24% Take‑over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033
Baheal PharmaceuticalFinance

Baheal’s 24% Take‑over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033

BMS Sells 60% Shanghai Stake to Hillhouse Capital, Shifting Focus to Growth
BMSBristol-Myers Squibb

BMS Sells 60% Shanghai Stake to Hillhouse Capital, Shifting Focus to Growth

Show More